Distribution of retroviral vectors and vector producer cells using two routes of administration in rats.
The clinical use of retroviral vector producer cells (VPCs) to deliver retroviral vectors efficiently to target cells has been investigated as a method to increase efficiency of gene delivery, presumably as a result of continued vector production in vivo. Studies were conducted in rats to evaluate the distribution of vector to distal organs and tissues as measured by transduction. Rats were treated with two doses of VPCs using two routes of administration: (1) subcutaneous injection, chosen to maximize both the dose and exposure of animals, thereby enabling identification of potential target organs under worst-case conditions; and (2) direct injection into brain parenchyma, chosen to mimic the intended clinical route of administration and provide an estimate of risk to patients receiving this therapy. Twelve organs or tissues were collected 7 days after administration of VPCs and analyzed by PCR for the presence of vector and vector producer cell sequences. Vector was detected most frequently at the site of injection by either route of administration. Less frequently, vector was detected in draining lymph nodes at the higher dose only using either route of injection. Single specimens of lung and contralateral skin were positive for vector following subcutaneous administration only. Vector was detected in gonadal tissue from a single low-dose male following subcutaneous administration, but this finding was not reproduced in any high-dose male or any males injected intracerebrally. In contrast, VPCs were detected only at the site of administration. The frequency of detection of VPCs 7 days after administration was higher when rats were injected by the intracerebral route. Based on these studies, gene transfer to distal organs or gonadal tissue following intracerebral administration of VPCs is not considered to be a risk to patients undergoing retroviral vector gene therapy for the treatment of brain cancer (glioblastoma multiforme; GBM).
Kaloss
M
M
Genetic Therapy, Inc, 938 Clopper Road, Gaithersburg, MD 20878, USA.
Linscott
M
M
Wey
C
C
Lu
P
P
Long
Z
Z
McGarrity
G J
GJ
Otto
E
E
Lyons
R M
RM
D000818:Animals; D001921:Brain / Q000821:virology; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000302:isolation & purification / Q000493:pharmacokinetics; D007271:Injections, Intradermal; D007276:Injections, Intraventricular; D008168:Lung / Q000821:virology; D008198:Lymph Nodes / Q000821:virology; D008297:Male; D016133:Polymerase Chain Reaction / Q000379:methods; D051381:Rats; D011916:Rats, Inbred F344; D012680:Sensitivity and Specificity; D018139:Simplexvirus / Q000235:genetics*; D012867:Skin / Q000821:virology; D013737:Testis / Q000821:virology